AGIOCongressional Stock Trades
Agios Pharmaceuticals, Inc.
Pharmaceutical Preparations
Congressional stock trades in Agios Pharmaceuticals, Inc. (AGIO) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
4
Politicians Trading
1
Last Traded
Aug 20, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr.D | Sep 10, 2026 | Aug 20, 2026 | Buy | $1,001 - $15,000 | -10.94% |
| Gilbert Ray Cisneros, Jr.D | Jan 12, 2026 | Dec 11, 2025 | Buy | $1,001 - $15,000 | +9.07% |
| Gilbert Ray Cisneros, Jr.D | May 6, 2025 | Apr 17, 2025 | Buy | $1,001 - $15,000 | +8.28% |
| Gilbert Ray Cisneros, Jr.D | Feb 11, 2025 | Jan 29, 2025 | Buy | $1,001 - $15,000 | -11.21% |
Price History
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
1 members of Congress have disclosed 4 trades in Agios Pharmaceuticals, Inc. (AGIO). Most active: Gilbert Ray Cisneros, Jr. (4).
Across all disclosures, members of Congress reported 4 purchases and 0 sales of Agios Pharmaceuticals, Inc. (AGIO). The most recent trade was on Aug 20, 2026.
Gilbert Ray Cisneros, Jr. disclosed buying Agios Pharmaceuticals, Inc. (AGIO) on Aug 20, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.